Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+)

Area of Science:

• Neuropathology
• Cerebrovascular Diseases
• Neurodegenerative Diseases

Background:

• Capillary amyloid-β (capAβ) deposition is a key feature differentiating Cerebral Amyloid Angiopathy (CAA) into Type 1 (with capAβ) and Type 2 (without capAβ).
• Understanding capAβ's role is crucial for classifying and understanding CAA.

Purpose of the Study:

• To investigate the neuropathological and clinical characteristics of capAβ deposition.
• To analyze the association between capAβ, CAA severity, Alzheimer's disease (AD) pathology, and genetic factors.

Main Methods:

• A population-based study of 300 individuals aged ≥85 years from the Vantaa 85+ cohort.
• Immunohistochemistry was used to diagnose capAβ and CAA, with severity graded semi-quantitatively.
• APOE genotype and AD-type neuropathology (CERAD score, Braak stage) were assessed.

Main Results:

• CAA-Type 1 was identified in 86/300 individuals, predominantly in the occipital lobe.
• CAA-Type 1 showed significant associations with increased CAA severity, dementia, severe AD-type neuropathology, and APOE ɛ4 allele carrier status.
• capAβ deposition was most frequent in the occipital lobe.

Conclusions:

• The study confirms distinct CAA-Type 1 characterized by capAβ deposition.
• capAβ presence is associated with more severe CAA, advanced AD neuropathology, and APOE ɛ4 carrier status.
• The clinical significance of capAβ appears dependent on its severity and brain region of deposition.